How Cancer Cells Evade Chemotherapy Outlined in New Study

A recent study published in Nature Metabolism reveals the mechanisms by which cancer cells evade chemotherapy, specifically drugs that target their metabolic pathways. Chemotherapies, particularly antimetabolics like raltitrexed, PALA, and brequinar, aim to disrupt pyrimidine synthesis, essential for DNA and RNA production in rapidly dividing cancer cells. However, cancer cells adapt by altering their metabolism to survive these treatments.

Conducted by researchers at NYU Langone Health and Perlmutter Cancer Center, the study highlights how cancer cells manage to persist in low-glucose environments, typical of tumor microenvironments. These environments hinder the effectiveness of chemotherapies by stalling the consumption of uridine nucleotides, crucial for cancer cell metabolism and growth. Normally, glucose is required to convert uridine into its active form, UDP-glucose. In low-glucose conditions, this conversion is impaired, slowing down cell death processes.

Additionally, the study found that low-glucose environments prevent the activation of proteins BAX and BAK on mitochondria surfaces. These proteins are critical for initiating apoptosis through caspase enzymes. Without their activation, cancer cells avoid destruction despite chemotherapy.

The findings suggest that understanding these metabolic adaptations could lead to more effective treatment strategies. By designing therapies that mimic stable glucose conditions or trick cancer cells into consuming their nucleotide reserves faster, it may be possible to enhance chemotherapy efficacy. Diagnostic tests could also be developed to predict a patient's response to low-glucose environments and specific chemotherapies.

Future research will explore blocking other pathways to induce apoptosis in cancer cells. Some experimental drugs like Chk-1 and ATR inhibitors show potential but require further investigation due to patient tolerance issues.